Guangzhou Darui Biotechnology
In-vitro diagnostic products for precision medicine applications
About Guangzhou Darui Biotechnology
In 2003, in the burgeoning metropolis of Guangzhou, a new entity was born not from a garage, but from the established prowess of a university. Guangzhou Darui Biotechnology emerged as a subsidiary of DAAN Gene Co., Ltd. of Sun Yat-sen University, starting its life with a clear mission: to innovate in molecular diagnostics. The company focused on developing high-tech platforms for critical health screenings, including prenatal, tumor, and infectious disease testing. This wasn't a story of a single product, but of building a comprehensive technological arsenal encompassing gene sequencing, mass spectrometry, and gene chip platforms to serve the clinical market. A pivotal moment arrived on July 9, 2015, when Darui Biotechnology was listed on the National Equities Exchange and Quotations, also known as the New Third Board in China. This step provided the resources to further its research and expand its footprint. The company continued to build, and under the leadership of figures like Chairman Dr. Ming Li, it forged key partnerships. A significant later-stage venture capital funding round of over $33 million in 2021 underscored investor confidence in its growth trajectory. Today, Darui stands as a key player in China's in-vitro diagnostic field, a testament to its strategic university origins and focused execution.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Oncology, Genetics and genomics, Techbio, DT and LS, science-based
- Technology
- Deep Tech
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2022 | $33M | $132M | Lanting Capital · CMB International · Platanus Ventures · Lilly Asia Ventures | ↗ |
Growth signals
Latest recorded traffic for Guangzhou Darui Biotechnology is 1.3K monthly website visits, up 664.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Guangzhou Darui Biotechnology in the Guangzhou ecosystem
The Guangzhou Darui Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- LCLanting Capital
- CICMB International
Platanus Ventures
Lilly Asia Ventures- FIFengchuan Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Guangzhou Darui Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Guangzhou Darui Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









